Skip to main content
. 2014 Dec 11;1(4):e47. doi: 10.1212/NXI.0000000000000047

Figure. Meta-analysis showing the influence of HLA-DRB1*13/*14 and HLA-DRB1*15 in the development of anaphylactic/anaphylactoid reactions to natalizumab in the different study cohorts.

Figure

Meta-analysis showing the influence of HLA-DRB1*13/*14 (A) and HLA-DRB1*15 (B) in the development of anaphylactic/anaphylactoid reactions to natalizumab in the different study cohorts. Forest plots showing the overall data and data after eliminating heterogeneity by removing the Spanish cohort. CI = confidence interval; HLA = human leukocyte antigen; HN+/HN− = patients who developed and did not develop anaphylactic/anaphylactoid reactions, respectively; M–H = Mantel-Haenszel.